NDA 021303 · Takeda Pharms USA
Adderall Xr 10
Amphetamine Aspartate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate · Oral
Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Oct 11, 2001
Approved uses
3
Original approval plus efficacy supplements
Registered trials
5
3 Phase 3, 0 recruiting
FAERS reports
41,907
18,198 serious, 515 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ABUSE, MISUSE, and ADDICTION ADDERALL XR ® has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including ADDERALL XR, can result in overdose and death [see Overdosage ( 10 )] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing ADDERALL XR, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout ADDERALL XR treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions ( 5.1 ), Drug Abuse and Dependence ( 9.2 )] . WARNING: ABUSE,...
What it is approved for
From the label in effect Apr 30, 2026.
ADDERALL XR, a CNS stimulant, is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. ( 1 ) Limitations of Use The use of ADDERALL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage. ( 5.5 , 8.4 ) 1.1 Attention Deficit Hyperactivity Disorder ADDERALL XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. Limitations of Use The use of ADDERALL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions ( 5.5 ), Use in Specific Populations ( 8.4 )].
Mechanism: Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 21, 2005 Supplement 9 · Efficacy · priority review ReviewPediatric Medical ReviewPediatric Written Request
- Aug 11, 2004 Supplement 5 · Efficacy ReviewLabelLetter
- Oct 11, 2001 Original approval · Type 3 - New Dosage Form LabelLetterReview
6 products under this application
- ADDERALL XR 10 · AMPHETAMINE ASPARTATE 2.5MG; AMPHETAMINE SULFATE 2.5MG; DEXTROAMPHETAMINE SACCHARATE 2.5MG; DEXTROAMPHETAMINE SULFATE 2.5MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB1
- ADDERALL XR 15 · AMPHETAMINE ASPARTATE 3.75MG; AMPHETAMINE SULFATE 3.75MG; DEXTROAMPHETAMINE SACCHARATE 3.75MG; DEXTROAMPHETAMINE SULFATE 3.75MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB1
- ADDERALL XR 25 · AMPHETAMINE ASPARTATE 6.25MG; AMPHETAMINE SULFATE 6.25MG; DEXTROAMPHETAMINE SACCHARATE 6.25MG; DEXTROAMPHETAMINE SULFATE 6.25MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB1
- ADDERALL XR 20 · AMPHETAMINE ASPARTATE 5MG; AMPHETAMINE SULFATE 5MG; DEXTROAMPHETAMINE SACCHARATE 5MG; DEXTROAMPHETAMINE SULFATE 5MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB1
- ADDERALL XR 5 · AMPHETAMINE ASPARTATE 1.25MG; AMPHETAMINE SULFATE 1.25MG; DEXTROAMPHETAMINE SACCHARATE 1.25MG; DEXTROAMPHETAMINE SULFATE 1.25MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB1
- ADDERALL XR 30 · AMPHETAMINE ASPARTATE 7.5MG; AMPHETAMINE SULFATE 7.5MG; DEXTROAMPHETAMINE SACCHARATE 7.5MG; DEXTROAMPHETAMINE SULFATE 7.5MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB1
Clinical trials
Interventional ClinicalTrials.gov studies with "Amphetamine Aspartate" as an intervention, any sponsor and status, largest first.
- Safety of SPD465 in Treating Adults With ADHD.Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT00152035 · 505 participants · Start Mar 10, 2005 · Primary completion Nov 7, 2006
Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate. · For: Attention Deficit Disorder With Hyperactivity
- Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT00152022 · 412 participants · Start Apr 25, 2005 · Primary completion Nov 4, 2005
Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate. · For: Attention Deficit Disorder With Hyperactivity
- Efficacy and Safety of SPD465 in Adults With ADHDPivotal-lookingCompleted
ShireTakeda (TAK)
NCT00150579 · 240 participants · Start Jan 27, 2005 · Primary completion Jun 14, 2005
Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate · For: Attention Deficit Disorder With Hyperactivity
ShireTakeda (TAK)
NCT00202605 · 72 participants · Start Sep 29, 2005 · Primary completion Jan 6, 2006
Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate · For: Attention Deficit Disorder With Hyperactivity
Sites: Little Rock, Arkansas; Irvine, California; Las Vegas, Nevada · 4 sites in all
ShireTakeda (TAK)
NCT03327402 · 24 participants · Start Mar 13, 2018 · Primary completion Oct 5, 2018
Drug: SHP465 · For: Attention Deficit Hyperactivity Disorder (ADHD)
Sites: Little Rock, Arkansas; Orlando, Florida; Evansville, Indiana · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,838
- fatigue3,271
- nausea2,969
- headache2,700
- anxiety2,546
- depression2,150
- feeling abnormal2,034
- pain1,805
- dizziness1,792
- somnolence1,743
- insomnia1,642
- off label use1,517
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 36 |
| 2005 | 38 |
| 2007 | 25 |
| 2008 | 5 |
| 2009 | 7 |
| 2010 | 25 |
| 2011 | 63 |
| 2012 | 374 |
| 2013 | 892 |
| 2014 | 1,261 |
| 2015 | 3,395 |
| 2016 | 7,276 |
| 2017 | 3,081 |
| 2018 | 3,384 |
| 2019 | 3,220 |
| 2020 | 2,918 |
| 2021 | 2,302 |
| 2022 | 2,889 |
| 2023 | 3,054 |
| 2024 | 2,862 |
| 2025 | 2,860 |
| 2026 | 1,940 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Takeda · Also marketed as Adderall Xr 15, Adderall Xr 25, Adderall Xr 20, Adderall Xr 5, Adderall Xr 30
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.